Cadrenal Therapeutics (NASDAQ:CVKD) CEO Quang Pham Sells 6,476 Shares

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) CEO Quang Pham sold 6,476 shares of Cadrenal Therapeutics stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $5.76, for a total transaction of $37,301.76. Following the sale, the chief executive officer owned 188,448 shares of the company’s stock, valued at approximately $1,085,460.48. This represents a 3.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Cadrenal Therapeutics Trading Down 1.8%

Shares of NASDAQ:CVKD traded down $0.09 during trading on Friday, hitting $4.91. 28,017 shares of the company’s stock were exchanged, compared to its average volume of 54,242. Cadrenal Therapeutics, Inc. has a 1-year low of $4.21 and a 1-year high of $15.99. The firm has a 50-day moving average price of $5.35 and a two-hundred day moving average price of $7.20. The firm has a market cap of $14.09 million, a P/E ratio of -0.87 and a beta of 1.81.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.51) by $0.47. As a group, research analysts predict that Cadrenal Therapeutics, Inc. will post -5.52 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. DRW Securities LLC bought a new position in Cadrenal Therapeutics in the fourth quarter valued at approximately $171,000. Citadel Advisors LLC bought a new position in Cadrenal Therapeutics in the third quarter valued at approximately $274,000. JPMorgan Chase & Co. bought a new position in Cadrenal Therapeutics in the third quarter valued at approximately $103,000. Finally, Geode Capital Management LLC lifted its stake in Cadrenal Therapeutics by 14.3% in the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after buying an additional 1,818 shares in the last quarter. Institutional investors and hedge funds own 7.92% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on CVKD shares. HC Wainwright decreased their price objective on shares of Cadrenal Therapeutics from $32.00 to $13.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Wall Street Zen upgraded shares of Cadrenal Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.00.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.